Feds scoop up a band of biotech in­sid­ers who al­leged­ly bagged a wind­fall, and now crim­i­nal charges

Ear­ly last year, in­vestors in Cela­tor picked up a 72% pre­mi­um when Jazz swooped in to buy the com­pa­ny and its lead drug for acute myeloid leukemia for $1.5 bil­lion in cash. And ac­cord­ing to fed­er­al in­ves­ti­ga­tors, a CPA at Cela­tor con­spired with friends to bag a quick wind­fall in the buy­out and for the pos­i­tive clin­i­cal tri­al da­ta for Vyx­eos that in­spired the deal and quadru­pled the biotech’s share price.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER